FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379982014> ?p ?o ?g. }

• W4379982014 endingPage "528" @default.
• W4379982014 startingPage "527" @default.
• W4379982014 abstract "Background: The redundancy of CD28 and CD3 signaling in a CAR design incorporating all 3 immunoreceptor tyrosine-based activation motifs (ITAMs) might negatively affect T cell differentiation and promote exhaustion. Therefore, we created a novel CD19 CAR construct with calibrated CAR signaling potential by mutating 2 of the 3 ITAMs, termed 1XX. In mouse models, 19-28z1XX CAR successfully induced tumor eradication at low CAR T cell doses with improved survival compared to conventional 19-28z CAR and with enhanced persistence of functional CAR T cells. We report on adult pts with DLBCL treated with 19(T2)28z-1XX CAR T cells (NCT04464200). Methods: This is a single center, phase I, dose-escalation and expansion trial of 19(T2)28z1XX CAR T cells in adult pts with R/R DLBCL. Pts received lymphodepleting chemotherapy followed by escalating doses of CAR T cells: 25–200 × 106. The primary objective was to evaluate safety and tolerability and determine the recommended phase 2 dose. Secondary objectives include overall response rate and duration of response. Results: Sixteen pts were treated on the dose escalation phase of the study. Median age was 62 (range, 50–80), and median number of prior treatments was 2 (range, 1–5). 4, 6, 3 and 3 pts were treated at DL1, DL2, DL3 and DL4 CAR T cells, respectively. 15 pts (94%) experienced cytokine release syndrome (CRS): grade 1 (n = 9), grade 2 (n = 6). No pts experienced ≥ grade 3 CRS. Two pts (13%) experienced neurotoxicity (NTX): 1 pt with grade 1 and 1 pt with grade 3. NTX was transient and reversible in both cases.Ten of 16 pts (63%) achieved a complete response (CR) and 2 pts (13%) achieved a partial response (PR), with overall response rate (ORR) of 75%. One pt who achieved initial PR spontaneously converted to CR without further treatment after month 6, resulting in best CR rate of 69%. Responses were seen across all dose levels. With a median follow-up of 155 days (range, 33–667), no pt in CR has experienced relapse including 7 pts with >6 months of follow-up (Figure 1). Peak CAR T cell expansion occurred at a median of 14 days after CAR T cell infusion (range, 7–83.3 days). CAR T cell detection beyond 350 days has been noted. DL 1 (25 × 10e6 cells) was chosen as the recommended dose for the expansion phase. Updated responses in the dose escalation cohort and the full expansion cohort, as well as PK data, will be presented. Conclusions: Treatment with 19(T2)28z1XX CAR T cells was safe. No severe CRS was observed and only 1 pt experienced transient grade 3 NTX. The overall CR rate was 69% and durable with no relapse observed with a median follow-up of 155 days. CRs were observed at DL1, which was chosen for the expansion phase. These findings corroborate our preclinical data and suggest that the 1XX signaling domain may lead to enhanced efficacy of CD19 CAR and allow infusion of a lower T cell dose with favorable toxicity profile. Keyword: Cellular therapies Conflicts of interests pertinent to the abstract. M. L. Palomba Consultant or advisory role: Synthekine, Cellectar, Kite, Bristol Meyer Squibb I. Riviere Consultant or advisory role: Fate Therapeutics, Akron Biotechnology Stock ownership: Mnemo Therapeutics, J. Li Employment or leadership position: Takeda L. Sellner Employment or leadership position: Takeda M. Sadelain Consultant or advisory role: Atara Research funding: Takeda, Mnemo Therapeutics S. Chen Employment or leadership position: Takeda Y. Zhao Employment or leadership position: Takeda J. H. Park Consultant or advisory role: Novartis, Kite, Kura, Astra-Zeneca, Servier, Curocell, Intella, Autolus, Allogene, Affymmune, Amgen Research funding: Genentech" @default.
• W4379982014 created "2023-06-10" @default.
• W4379982014 creator A5004668472 @default.
• W4379982014 creator A5016575685 @default.
• W4379982014 creator A5025983003 @default.
• W4379982014 creator A5034388262 @default.
• W4379982014 creator A5036831073 @default.
• W4379982014 creator A5052659722 @default.
• W4379982014 creator A5056473026 @default.
• W4379982014 creator A5059625599 @default.
• W4379982014 creator A5061453480 @default.
• W4379982014 creator A5062885345 @default.
• W4379982014 creator A5078029371 @default.
• W4379982014 creator A5078894628 @default.
• W4379982014 creator A5084981161 @default.
• W4379982014 date "2023-06-01" @default.
• W4379982014 modified "2023-10-17" @default.
• W4379982014 title "A Phase I Study of CD19‐targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B‐cell Lymphoma" @default.
• W4379982014 doi "https://doi.org/10.1002/hon.3164_390" @default.
• W4379982014 hasPublicationYear "2023" @default.
• W4379982014 type Work @default.
• W4379982014 citedByCount "0" @default.
• W4379982014 crossrefType "journal-article" @default.
• W4379982014 hasAuthorship W4379982014A5004668472 @default.
• W4379982014 hasAuthorship W4379982014A5016575685 @default.
• W4379982014 hasAuthorship W4379982014A5025983003 @default.
• W4379982014 hasAuthorship W4379982014A5034388262 @default.
• W4379982014 hasAuthorship W4379982014A5036831073 @default.
• W4379982014 hasAuthorship W4379982014A5052659722 @default.
• W4379982014 hasAuthorship W4379982014A5056473026 @default.
• W4379982014 hasAuthorship W4379982014A5059625599 @default.
• W4379982014 hasAuthorship W4379982014A5061453480 @default.
• W4379982014 hasAuthorship W4379982014A5062885345 @default.
• W4379982014 hasAuthorship W4379982014A5078029371 @default.
• W4379982014 hasAuthorship W4379982014A5078894628 @default.
• W4379982014 hasAuthorship W4379982014A5084981161 @default.
• W4379982014 hasBestOaLocation W43799820141 @default.
• W4379982014 hasConcept C126322002 @default.
• W4379982014 hasConcept C143998085 @default.
• W4379982014 hasConcept C167672396 @default.
• W4379982014 hasConcept C203014093 @default.
• W4379982014 hasConcept C2776090121 @default.
• W4379982014 hasConcept C2778559949 @default.
• W4379982014 hasConcept C2779338263 @default.
• W4379982014 hasConcept C2780850621 @default.
• W4379982014 hasConcept C3875195 @default.
• W4379982014 hasConcept C71924100 @default.
• W4379982014 hasConcept C8891405 @default.
• W4379982014 hasConcept C90924648 @default.
• W4379982014 hasConceptScore W4379982014C126322002 @default.
• W4379982014 hasConceptScore W4379982014C143998085 @default.
• W4379982014 hasConceptScore W4379982014C167672396 @default.
• W4379982014 hasConceptScore W4379982014C203014093 @default.
• W4379982014 hasConceptScore W4379982014C2776090121 @default.
• W4379982014 hasConceptScore W4379982014C2778559949 @default.
• W4379982014 hasConceptScore W4379982014C2779338263 @default.
• W4379982014 hasConceptScore W4379982014C2780850621 @default.
• W4379982014 hasConceptScore W4379982014C3875195 @default.
• W4379982014 hasConceptScore W4379982014C71924100 @default.
• W4379982014 hasConceptScore W4379982014C8891405 @default.
• W4379982014 hasConceptScore W4379982014C90924648 @default.
• W4379982014 hasIssue "S2" @default.
• W4379982014 hasLocation W43799820141 @default.
• W4379982014 hasOpenAccess W4379982014 @default.
• W4379982014 hasPrimaryLocation W43799820141 @default.
• W4379982014 hasRelatedWork W2251648452 @default.
• W4379982014 hasRelatedWork W2916176185 @default.
• W4379982014 hasRelatedWork W2917403768 @default.
• W4379982014 hasRelatedWork W2936186479 @default.
• W4379982014 hasRelatedWork W2952260713 @default.
• W4379982014 hasRelatedWork W2969241243 @default.
• W4379982014 hasRelatedWork W3028773865 @default.
• W4379982014 hasRelatedWork W3142239825 @default.
• W4379982014 hasRelatedWork W4220818326 @default.
• W4379982014 hasRelatedWork W4381594543 @default.
• W4379982014 hasVolume "41" @default.
• W4379982014 isParatext "false" @default.
• W4379982014 isRetracted "false" @default.
• W4379982014 workType "article" @default.